» Articles » PMID: 33651142

Early T-cell Precursor Acute Lymphoblastic Leukemia and Other Subtypes: a Retrospective Case Report from a Single Pediatric Center in China

Overview
Specialty Oncology
Date 2021 Mar 2
PMID 33651142
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is rare in China and case reports are varied. We conducted an in-depth analysis of newly diagnosed children with T-ALL from January 1999 to April 2015 in our center, to show the biological differences between Chinese ETP-ALL children and other immune types of T-ALL.

Methods: The newly diagnosed children with T-ALL were divided into four groups according to their immunophenotype: ETP-ALL, early non-ETP-ALL, cortical T-ALL and medullary T-ALL. Disease-free survival (DFS), event-free survival (EFS), and overall survival (OS) rates were estimated by the Kaplan-Meier method. The Cox regression model was used for multivariate analysis.

Results: A total of 117 newly diagnosed children with T-ALL were enrolled in this study. The 10-year EFS and OS rates for all patients were 59.0 ± 4.7% and 61.0 ± 4.7%, respectively, with a median follow-up of 64 (5-167) months. Univariate analysis showed that ETP-ALL patients had the lowest 10-year DFS rate of 32.1 ± 11.7%, while cortical T-ALL had the highest DFS rate of 81.3 ± 8.5% compared with early non-ETP-ALL (61.6 ± 7.0%) and medullary T-ALL (59.1 ± 10.6%). Multivariate analysis demonstrated that only ETP-ALL and involvement of the central nervous system were independent prognostic factors.

Conclusion: Compared with other subtypes, pediatric ETP-ALL had a poor treatment response and high recurrence rate while cortical T-ALL appeared to have much better outcome. Our observations highlight the need for an individualized treatment regime for ETP-ALL.

Citing Articles

Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL.

Onishi Y, Furukawa E, Kamata M, Fukatsu M, Kameoka Y, Hatta S Int J Hematol. 2023; 117(5):738-747.

PMID: 36757523 DOI: 10.1007/s12185-023-03546-6.


Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation.

Chen J, Liu L, Ma R, Pang A, Yang D, Chen X Front Oncol. 2023; 12:1025885.

PMID: 36686839 PMC: 9846781. DOI: 10.3389/fonc.2022.1025885.

References
1.
Arai N, Homma M, Abe M, Baba Y, Murai S, Watanuki M . Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia. Int J Hematol. 2019; 109(5):539-544. DOI: 10.1007/s12185-019-02616-y. View

2.
Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

3.
Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P . Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood. 2004; 104(13):4173-80. DOI: 10.1182/blood-2003-11-3944. View

4.
Bachman J . Reverse-transcription PCR (RT-PCR). Methods Enzymol. 2013; 530:67-74. DOI: 10.1016/B978-0-12-420037-1.00002-6. View

5.
Bene M, Castoldi G, Knapp W, Ludwig W, Matutes E, Orfao A . Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995; 9(10):1783-6. View